NCT06714825

Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics in Overweight/Obese Healthy Subjects

Phase 1 Single and Multiple Ascending Dose Study in Males and Females Assessing the Pharmacokinetics, Safety, and Pharmacodynamics of HS235 in Overweight and Obese Otherwise Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: 35Pharma Inc · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Accepted

Summary

Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics of HS235 in Overweight and Obese Otherwise Healthy Subjects

Detailed description

A Phase 1 Study Assessing the Pharmacokinetics, Safety, and Pharmacodynamics of HS235 in Overweight and Obese Otherwise Healthy Subjects: Single Ascending Dose (SAD) in Males and Postmenopausal Females and Multiple Ascending Dose (MAD) in Males and Females of Non-childbearing Potential

Conditions

• Overweight and Obesity

Interventions

Type	Name	Description
BIOLOGICAL	HS235	Up to 4 Single and 3 Multiple Ascending Doses
DRUG	Placebo	Subcutaneous Injection

Timeline

• Start date: 2024-11-28
• Primary completion: 2025-12-02
• Completion: 2025-12-02
• First posted: 2024-12-04
• Last updated: 2025-12-30

Locations

1 site across 1 country: Canada